NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Tiziana Life Sciences Ltd (TLSA) Stock Analysis

Tiziana Life Sciences Ltd (TLSA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TLSA

$1.01

$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TLSA with… →

TLSA Key Statistics

As of Oct 21, 2026
Trading
Open
$1.03
Previous Close
$1.01
Day's Range
0.97–1.03
52-Week Range
0.76–2.10
Volume
419.98K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.44
Valuation
Market Cap
$128.53M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.21
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$18.43M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
127.26M
1-Year Return
−46.56%
Dividend and dates
Avg Volume
766.09K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TLSA closed at $1.01, −46.56% over 1 year.

Tiziana Life Sciences Ltd (TLSA) has a market capitalization of $128.53M.

In fiscal 2025, TLSA reported revenue of $0.00.

TLSA Stock Return by Calendar Year

Tiziana Life Sciences Ltd (TLSA) return since Nov 2018: what $10,000 became

1 year
$10,000 $5,344
−46.56%
5 years
$10,000 $6,733
−32.67%
Since Nov 2018
$10,000 $6,045
−39.55%

If you had invested $10,000 in Tiziana Life Sciences Ltd (TLSA) at the close on November 20, 2018, the earliest close on record here, it would have been worth $6,045 at the close on October 21, 2026: −39.55% in total, −6.16% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−32.21%
2025+112.86%
2024+25.00%
2023−6.67%
2022−37.50%
2021−52.48%
2020+86.97%
2019−27.52%
2018 (partial year)−10.78%

As of October 21, 2026.

TLSA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$18.43M—
2024$0.00−$11.86M—
2023$0.00−$17.69M—
2022$0.00−$15.40M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$21.13M−$18.43M—
2024$0.00—−$15.79M−$11.86M—
2023$0.00—−$17.98M−$17.69M—
2022$0.00—−$14.59M−$15.40M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Tiziana Life Sciences Ltd (TLSA) carries a market capitalisation of $128.53M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 10.

The 52-week range on file runs from $0.76 to $2.10. TLSA last closed at $1.01 on October 21, 2026. The close was unchanged from the previous session. The latest close sits 32.89% above that 52-week low.

Financial Health

In fiscal 2025, Tiziana Life Sciences Ltd reported revenue of $0.00. The same year closed with a net loss of $18.43M. Trailing earnings per share are −0.21.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 0.44. Annualized volatility over the trailing 7 years is 111.15%. Over the trailing twelve months the total return is −46.56%. Measured over 5 years, that is −7.61% a year compounded.

Growth & Income

No dividend is on file for TLSA.

2026 is still running; the total return is −32.21% year to date. The strongest complete calendar year on file is 2025 at +112.86%; the weakest is 2021 at −52.48%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

Tiziana Life Sciences Ltd (TLSA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tiziana Life Sciences Ltd TLSA $128.53M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Tiziana Life Sciences Ltd has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.

Visit website →